Carlyle AlpInvest, HarbourVest Partners, Lexington Partners rolls Inflexion Continuation Fund I (Aspen Pumps, Rosemont Pharmaceuticals, Ocorian, CNX Therapeutics) into a continuation vehicle
for $3.1bn

Inflexion’s successful close of its £2.3 billion continuation fund represents a strategic pivot to monetize key portfolio companies while retaining ownership and growth potential. The acquisition of Aspen Pumps, Rosemont Pharmaceuticals, Ocorian, and CNX Therapeutics allows Inflexion to provide significant liquidity to existing investors with returns of 3.4x and a 28% IRR, totaling £1.5 billion in net proceeds. This transaction aligns with Inflexion’s broader strategy of leveraging M&A to accelerate growth for its portfolio companies. The continuation fund is structured as an equity buyout, with capital raised from Carlyle AlpInvest, HarbourVest Partners, and Lexington Partners as lead investors, alongside new and existing Inflexion funds. The deal is underwritten by Venero Capital Advisors, Jefferies, and William Blair as financial advisors to the Inflexion Funds, while Kirkland & Ellis serves as legal counsel. This transaction underscores Inflexion’s ability to execute complex capital structures, securing substantial funding for future growth initiatives. From a competitive standpoint, this deal fortifies Inflexion's market position in European private equity by demonstrating its capability to facilitate large-scale continuation funds and maintain control over portfolio companies’ strategic direction. It also signals increased M&A activity within the healthcare technology, pharmaceuticals, and industrial distribution sectors, potentially attracting more competitors seeking similar growth opportunities through consolidation. Post-close, key risks include securing regulatory approvals and navigating potential integration challenges among diverse businesses spanning different industries. However, Inflexion’s track record of successful exits and value creation suggests it is well-positioned to manage these risks effectively. The continuation fund will likely focus on further M&A activities, organic growth initiatives, and international expansion for the four acquired companies, positioning them to capture favorable market tailwinds in their respective sectors.